Asahi Kasei Pharma Denmark, a subsidiary of Asahi Kasei Corporation, has agreed to acquire Veloxis Pharmaceuticals in a deal worth DKK8.9 B (US$1.3 B) to gain access to Veloxis’ Envarsus XR® (tacrolimus extended release tablets), a once-daily immunosuppressant tablet approved for use in organ rejection. The deal comes after an eight-year pause in M&A deal making for the Asahi Kasei Group as it now looks to enhance its presence in the US following the acquisitions of Cardiac Science and TherOx in June 2019.